This panel discussion will feature the top minds in infectious diseases, virology and vaccinology, who will give participants a breakdown of the top vaccine candidates and the latest information on clinical trials.

GlaxoSmithKline and Germany-based CureVac forged a strategic collaboration worth nearly $1 billion to develop up to five messenger RNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens.

Glympse Bio secured $46.7 million in a Series B fundraising round that will be used to support continued development of the company’s novel biosensor platform in fibrotic diseases such as non-alcoholic steatohepatitis (NASH), oncology and infectious diseases.

The National Institute of Allergy & Infectious Diseases (NIAID) has founded a new clinical trials network focused on enrolling volunteers in clinical trials for COVID-19 vaccines and monoclonal antibodies.

Sanofi Pasteur and Lexington, Massachusetts-based Translate Bio announced the expansion of an existing collaboration to develop mRNA vaccines for infectious diseases.

The United States will end its relationship with the World Health Organization over the body’s handling of the coronavirus pandemic, U.S. President Donald Trump said, accusing the U.N. agency of becoming a puppet of China.

According to the Pharmaceutical Research and Manufacturers of America (PhRMA), there are 264 vaccines in development to prevent and treat diseases.

Vir Biotechnology priced the company’s initial public offering (IPO) at $20 a share, at the bottom end of expectations, the latest underwhelming investment performance for a stock held by SoftBank Group Corp.’s Vision Fund.

The new global pharmaceutical company combines Mylan N.V. with Upjohn, Pfizer Inc.’s off-patent branded and generic established medicines business.

Vancouver-based AbCellera and Gilead Sciences forged a collaborative agreement to discover and develop ultra-rare antibodies that can be used in the treatment of a number of infectious diseases.